Authors: Jasmine Harris, Future Science Group
New research, presented at the Alzheimer’s Association International Conference (21–26 July, IL, USA), focuses on the treatment of non-cognitive symptoms of individuals with Alzheimer’s disease (AD). Behavioral and psychological symptoms of dementia include: agitation, anxiety, apathy, depression, wandering, hallucinations, insomnia, incontinence and disinhibition, and these often cause the greatest challenges to caregivers and reduction in quality of life.
There are currently no US FDA-approved drug treatments for these symptoms associated with AD, and any treatments currently utilized to control the non-cognitive symptoms are approved for other indications and prescribed ‘off-label’.
“These under-recognized and undertreated symptoms in people with Alzheimer’s and other dementias are often very difficult to live with and challenging to treat,” commented Maria Carrillo, Alzheimer’s Association Chief Science Officer. “One of the ‘untold stories’ of Alzheimer’s is the regular occurrence and overwhelming impact of these symptoms on the lives of people with Alzheimer’s, their family members and caregivers.”